- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Pharmala Biotech Holdings Inc: Pharmala Biotech files final prospectus | 1 | Stockwatch | ||
| 03.11. | PharmAla Biotech: PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital | 190 | GlobeNewswire (Europe) | TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 09.10. | Pharmala Biotech Holdings Inc: Pharmala launches Nexus chain-of-care portal | 1 | Stockwatch | ||
| 08.10. | PharmAla Biotech: PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists | 3 | GlobeNewswire (USA) | ||
| 02.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech completes shipment to Johns Hopkins | 3 | Stockwatch | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 02.10. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Johns Hopkins | 2 | GlobeNewswire (USA) | ||
| 26.09. | Pharmala Biotech Holdings Inc: Pharmala enters distribution deal with Veridion | 3 | Stockwatch | ||
| 25.09. | PharmAla Biotech: PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand | 1 | GlobeNewswire (USA) | ||
| 19.09. | Pharmala Biotech Holdings Inc: Pharmala Biotech files amended preliminary prospectus | 1 | Stockwatch | ||
| 19.09. | PharmAla Biotech: PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
| 08.09. | PharmAla Biotech: PharmAla Completes Import of LaNeo MDMA for US Distribution | 72 | GlobeNewswire (Europe) | TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 04.09. | Pharmala Biotech Holdings Inc: Pharmala incorporates Ausi unit for clinical research | 2 | Stockwatch | ||
| 03.09. | PharmAla Biotech: PharmAla Incorporates Australian Entity for Clinical Research | 1 | GlobeNewswire (USA) | ||
| 08.08. | Pharmala Biotech Holdings Inc: Pharmala delivers 500 capsules of MDMA to Merhavim | 2 | Stockwatch | ||
| 07.08. | PharmAla Biotech: PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License | 1 | GlobeNewswire (USA) | ||
| 26.07. | Pharmala Biotech Holdings Inc: Pharmala omits Q3 net P&L in NR, talks expenses | 2 | Stockwatch | ||
| 25.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements | 646 | GlobeNewswire (Europe) | TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 20.06. | Pharmala Biotech Holdings Inc: Pharmala files prospectus to issue $50M of securities | 1 | Stockwatch | ||
| 20.06. | PharmAla Biotech: PharmAla Files Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
| 04.06. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to Yale | 2 | Stockwatch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| HARMONY BIOSCIENCES | 35,290 | -0,76 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results | ||
| ARCUTIS BIOTHERAPEUTICS | 30,650 | -1,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,630 | +4,99 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| COGENT BIOSCIENCES | 40,250 | -0,35 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| DAY ONE BIOPHARMACEUTICALS | 9,490 | +0,85 % | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 43,110 | -0,58 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 17,900 | +0,45 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 84,12 | +0,55 % | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.